HealthTechPublicTransactional
Veracyte
Genomic diagnostics company using AI for cancer diagnosis. Revenue grew from $40M to $350M+ by replacing invasive biopsies with genomic tests.
Founded: 2008South San Francisco800-1,200 employeesFunding: $500,000,000
Transactional (per test)
revenueModel
Growth Timeline
2008
Founded
2010
Product-market fit
2012
Growth acceleration
Tools & Technology
Lessons Learned
- 1.Clinical evidence drives adoption in HealthTech
- 2.Payer relationships are as important as clinical ones
- 3.Genomic data creates compounding advantages
Ehsan's Growth Analysis
Veracyte demonstrates HealthTech growth through clinical evidence compounding. Each published study increases physician confidence, which drives more test orders, which generates more data for better tests. This flywheel took 10 years to build but creates a moat that is nearly impossible to replicate.
EJ
Ehsan Jahandarpour
AI Growth Strategist & Fractional CMO
Forbes Top 20 Growth Hacker · TEDx Speaker · 716 Academic Citations · Ex-Microsoft · CMO at FirstWave (ASX:FCT) · Forbes Communications Council
Frequently Asked Questions
How did Veracyte grow?
Veracyte demonstrates HealthTech growth through clinical evidence compounding. Each published study increases physician confidence, which drives more test orders, which generates more data for better
What growth tactics does Veracyte use?
Veracyte uses Content Marketing, Partnerships.
What tools does Veracyte use?
Key tools include AWS, Snowflake, Salesforce.